
GBS Vaccine Receives FDA Breakthrough Therapy Designation
On September 7, Pfizer announced that its GBS vaccine candidate GBS6 (PF-06760805) has been granted breakthrough therapy designation by the FDA for the prevention of
On September 7, Pfizer announced that its GBS vaccine candidate GBS6 (PF-06760805) has been granted breakthrough therapy designation by the FDA for the prevention of